INTRODUCTION
There is currently insufficient evidence from randomized controlled trials (RCTs) to determine whether 25-hydroxyvitamin D [25(OH)D] targets specific for perinatal outcomes are required (1) (2) (3) (4) . Thus, Dietary Reference Values for vitamin D, which are the recommended intakes to meet 25(OH)D targets of between 25 and 50 nmol/L for bone health outcomes, have been extended to pregnancy and lactation (summarized in Table 1 ) (5) . Although setting Dietary Reference Values is an iterative process, reliant on the evidence basis at that time, the current recommendations for vitamin D during pregnancy suffer from a lack of evidence across a number of criteria. Not only are they not specific for perinatal health outcomes, they do not consider fetal and neonatal requirements specifically and rely on an assumption that pregnancy does not increase the metabolic demand for vitamin D.
Endemic vitamin D deficiency has been reported among pregnant women and newborns worldwide, with wide variations between and within regions. In the systematic review by Saraf et al. (6) , the global prevalence of 25(OH)D concentrations <50 nmol/L was 54% among pregnant women and 75% among newborns, whereas 18% of pregnant women and 29% of newborns had concentrations <25 nmol/L, a threshold identified as indicative of an increased risk of nutritional rickets (1) (2) (3) (4) . Acknowledging that neonatal requirements for 25(OH)D are unknown and the application of adult references to newborns may be questionable (7) , it seems prudent nonetheless to ensure maintenance of newborn circulating 25(OH)D above a minimum of 25-30 nmol/L, consistent with the prevention of nutritional rickets (8, 9) . Because cord 25(OH)D concentrations are usually ∼60-80% of maternal values at delivery (10, 11) , maintenance of maternal 25(OH)D >25-30 nmol/L will not ensure newborn protection at the same threshold. In the absence of sufficient trialbased data to set maternal requirements for 25(OH)D on the basis of perinatal outcomes, we propose in the interim that dietary recommendations for vitamin D during pregnancy should be established with the aim of maintaining maternal 25(OH)D in late gestation at sufficient concentrations to ensure that newborn 25(OH)D concentrations are ≥25-30 nmol/L. Researchers in New Zealand and Canada have proposed that maternal 25(OH)D should be maintained at 50 nmol/L (12, 13) . To our knowledge, this is the first placebo-controlled, dose-response, randomized trial that was designed specifically to estimate the maternal vitamin D intake needed to maintain serum 25(OH)D in late gestation at a concentration sufficient to keep umbilical cord 25(OH)D ≥25-30 nmol/L, a threshold indicative of increased risk of nutritional rickets.
METHODS
This trial was conducted as part of the European Commissionfunded collaborative project ODIN (Food-based solutions for optimal vitamin D nutrition and health throughout life; www.odin-vitd.eu). This study was a 3-arm, parallel, dose-response, double-blind, randomized trial of vitamin D 3 (cholecalciferol) compared with placebo.
Participants
A total of 144 healthy, pregnant women were recruited to the trial. Recruitment began in November 2014 and continued until April 2016. The primary center for recruitment was the Cork University Maternity Hospital, Cork, Ireland, where women attending early pregnancy and ultrasound clinics were approached by a member of the study team and informed about the trial. Social media and advertisements in local General Practitioners surgeries and pharmacies provided another avenue for recruitment. Women were considered eligible for participation if they were white-skinned adults ≥18 y of age, with a gravidae of ≤18 wk of gestation, in good general health, and not identified as having a high-risk pregnancy. Exclusion criteria were as follows: current smoker, vegan, diagnosed hypertension before commencement of the study, diagnosed medical disorder including type 1 or 2 diabetes, chronic kidney disease or gastrointestinal disease, consumption of medications known to interfere with vitamin D metabolism (e.g., corticosteroids), and consumption of supplemental vitamin D [>10 µg/d (>400 IU)] or calcium (>650 mg/d) before randomization. Women were permitted to continue with selfadministration of antenatal supplements containing ≤10 µg vitamin D/d but were excluded from the study if personal supplement use exceeded this dose.
Sample size
The power calculation for this study was based on similar doseresponse studies of vitamin D nutritional requirements designed by our research group, whereby 31 participants/arm are adequate to detect a 10-nmol/L difference in 25(OH)D concentrations and provide 90% power to show a dose-response relation with a slope of 1.5 and α = 0.05 (14) (15) (16) (17) . Because this was a pregnancy study, with 3 assessment points at baseline and the second and third trimesters, it was implemented throughout the year, unlike our previous trials in other population subgroups, which were conducted during winter. Therefore, we increased the sample size to 48/arm (144 in total) to enable a season-specific analysis and to account for a potentially higher drop-out rate in late gestation than we would usually see (typically, ≤15%).
Ethics
Ethical approval was obtained from the Clinical Research Ethics Committee of the Cork Teaching Hospitals [ECM4(o)04/02/14] and written informed consent was provided by all women before commencing the trial. The study protocol followed the guidelines laid down in the Declaration of Helsinki, and the trial was registered at the US NIH Clinical Trials Registry (www.clinicaltrials.gov; ID: NCT02506439).
Randomization
Given that this was a single-sex sample, within the reproductive age range, women were randomly assigned to receive 10 µg (400 IU) or 20 µg (800 IU) vitamin D 3 /d or a matching placebo in a 1:1:1 ratio (Figure 1) . A senior scientist, who was not involved in the implementation or analysis of the study, randomly assigned group codes to a computer-generated list of random numbers, which were assigned to consecutive participant identification numbers. Participants were allocated an identification number in order of attendance of the baseline visit. The treatment allocation was blinded to participants and investigators throughout the study period.
Intervention
Placebo and Minisun vitamin D 3 tablets were provided by OY Verman Ab. All tablets (placebo and 10-and 20-µg vitamin D 3 ) were identical in appearance and taste and free from sugar, lactose, yeast, gluten, and gelatin. Tablets were packaged and coded into identical, white, plastic containers in a food sensory facility at our center, ensuring concealment of the treatment to the study team and participants. Independent analysis of the vitamin D content of the study tablets was conducted by liquid chromatography-tandem mass spectrometry (LC-MS/MS) at the National Food Institute at the Technical University of Denmark. All of the analyses were based on a sample of 5 tablets and were performed in triplicate. The content of the placebo and the 10-and 20-µg labeled tablets corresponded to a value of <0.02, 10.9, and 22.4 µg vitamin D 3 , respectively. The dose range of vitamin D was chosen on the basis of the distribution of intakes and 25(OH)D concentrations observed in our previous dose-response vitamin D trials (14, 15) . We estimated that the mean intake in the 20 µg group would be ∼25 µg/d (1000 IU), accounting for the average contribution of the diet to vitamin D intakes in Ireland (18) . In the current study, given that women were allowed to continue with their own supplements as long as these did not provide >10 µg/d, we estimated that the range of total intakes in the sample from the base diet, fortified foods, personal antenatal supplements, and assigned trial supplements would lie between 1 and ∼50 µg/d. We aimed to include a supplemental dose that would ensure a total vitamin D intake that would not exceed the accepted Tolerable Upper Intake Level of 100 µg/d (1). All of the participants received a container of 90 tablets at both the baseline and midpoint visits, corresponding to 1 tablet/d for up to 14 wk. Compliance was monitored by a tablet count at each visit, and noncompliance was defined a priori as tablet consumption <80%.
Data collection
All of the study visits took place at the Human Nutrition Studies Unit at the Cork Center for Vitamin D and Nutrition Research, University College Cork, Cork, Ireland. The RCT was conducted in compliance with Good Clinical Practice. Participants were seen 3 times throughout their pregnancy: at baseline (14 wk of gestation; range: 8-18 wk), midgestation (24 wk of gestation; range: 20-26 wk), and late gestation (36 wk of gestation; range: 34-38 wk). Gestational age was established by date of last menstrual period and confirmed by fetal ultrasound at the participants' first ultrasound visit. At baseline, interviewer-led assessments collected information on general health, lifestyle, and sociodemographic characteristics. Habitual calcium and vitamin D intakes were estimated by using a validated intervieweradministered quantitative food-frequency questionnaire for vitamin D and calcium (19) at baseline, and antenatal supplement use was re-assessed at the second and third study visit to account for any changes in supplemental vitamin D or calcium intake. Anthropometric measurements (height and weight) were taken at baseline with the use of standard scales (Leicester height measure; CMS Weighing Equipment Ltd.; digital weighing scales; Seca Ltd.), and body weight measurements were repeated at the second and third visits. Weight was measured in kilograms, without shoes or heavy clothing, to the nearest 2 decimal places. A venous nonfasting blood sample (30 mL) was collected at each visit, because it would be inappropriate to request a pregnant woman to fast. Blood samples were taken by a research nurse and processed to serum within 3 h. A venous umbilical cord blood sample was collected at delivery, refrigerated immediately, and processed to serum at University College Cork. All of the blood samples were stored at -80˚C until further analysis.
Laboratory analysis

Serum 25(OH)D concentrations
Circulating serum 25- 1 CONSORT flow diagram of participant enrollment, random assignment, and biochemical analysis throughout the study by treatment group, where n is based on the total number of samples available for each visit. Any participant who did not provide a blood sample at baseline was included in the descriptive and biochemical analysis at later time points but excluded from the dose-response analysis, whereas women missing a midpoint sample only were included in both the dose-response analysis and the analysis at endpoint, if a blood sample was collected at this time point. The numbers of women who provided both a baseline and ≥1 follow-up sample (midpoint or endpoint) were 43, 42, and 43 for the placebo and 10-and 20-µg groups, respectively, which left a final number of 128 for the dose-response analysis. CONSORT, Consolidated Standards of Reporting Trials; inclu., including. −1.5%, −4.9%, 12.0%, and −1.7%, respectively. Our method does not measure the C-3 epimer of 25(OH)D 2 , but given the low mean ± SD concentrations of 25(OH)D 2 found in sera from pregnant women (3.7 ± 2.7 nmol/L) (20) and umbilical cords (2.2 ± 1.9 nmol/L) (9), extremely low concentrations of 3-epi-25(OH)D 2 would be expected.
The quality and accuracy of the vitamin D metabolite analysis in our laboratory are monitored on an ongoing basis by participation in the Vitamin D External Quality Assessment Scheme (DEQAS; Charing Cross Hospital, London, United Kingdom). 
Serum calcium concentrations
As a safety measure, serum calcium is preferable to urinary calcium in studies involving pregnant women because physiologic hypercalciuria can occur as a result of normal pregnancy (1) . Serum calcium and albumin were quantified at our laboratory by colorimetric and immunoturbidimetric assays, respectively, with the use of the Randox Monaco Automated Clinical Chemistry Analyser (Randox Laboratories Ltd., Co.). Serum calcium was corrected for albumin as follows: corrected calcium
, where 40 represents the average albumin concentration in grams per liter (22) . Batch analysis allowed for continuous sampling throughout the trial to ensure that all participants remained below the predefined safety threshold (hypercalcemia defined as serum calcium ≥2.63 mmol/L) (1) . A normal reference range of 2.02-2.60 mmol/L is in agreement with that provided by the manufacturer of the equipment used in this laboratory (Randox Monaco, Randox Laboratories Ltd., Co.). The mean interassay CV for the analysis was 3%.
Serum parathyroid hormone concentrations
Serum intact parathyroid hormone (iPTH) was analyzed at baseline and endpoint at our laboratory with the use of an ELISA (MD Biosciences, Inc.) on the automated Dynex DS2 ELISA processing platform (Dynex Technologies). This 2-site assay is designed to measure biologically iPTH 1-84 and utilizes 2 purified goat polyclonal antibodies, each specific to a distinct region on the parathyroid hormone (PTH) molecule. A biotinylated antibody binds to midregion and C-terminal PTH 39-84. The detection antibody, a horseradish peroxidase-conjugated antibody, binds N-terminal PTH 1-34. The mean intra-and interassay CVs for this analysis were <3%.
Statistical analysis
Statistical analysis was conducted with the use of SPSS for Windows version 23.0 (released 2015; IBM Corp., Armonk, NY, USA). Distribution of the data for all variables at baseline was tested for normality with the use of histograms and formal tests (Kolmogorov-Smirnov and Shapiro-Wilk). Data are presented as means ± SDs, medians (IQRs), and frequencies with percentages, where appropriate. Where data could not be normalized after transformation, the alternative nonparametric tests were used. A Mann-Whitney U test assessed the difference in participant characteristics between women who completed the trial and women who had either withdrawn or for whom data were missing at any stage. Pre-and postintervention 25(OH)D status and iPTH concentrations within each group were compared by using paired t tests, as were differences between maternal and umbilical cord vitamin D metabolites. For continuous data, a between-group ANOVA with post hoc Tukey's test was used to assess the differences in participant characteristics, biochemical measures, and dietary intakes between the 3 arms of the trial and a mixed within-between-subject ANOVA assessed changes in biochemical measures between the groups over time. For comparison between categorical variables, including the proportion of women achieving serum 25(OH)D concentration thresholds of ≥25, 30, 40, 50, and 75 nmol/L, chi-square tests were used. Bivariate correlations between variables were examined by using Pearson or Spearman correlations, where appropriate. Season of sampling was dichotomized into winter (NovemberMay) and summer (June-October). Associations between maternal and umbilical cord vitamin D metabolites, vitamin D intakes, and iPTH were described by using a linear trendline or power best-fit curve, where appropriate. P < 0.05 was considered significant.
Mathematical modeling of distribution of serum 25(OH)D in relation to total vitamin D intake
Total vitamin D intake was assessed as habitual dietary intake plus that derived from personal antenatal supplementation, if used, plus the intervention dose from the assigned treatment, on the basis of the analytically verified vitamin D content of the tablets. The relation between total vitamin D intake and postintervention serum 25(OH)D was described by using the curvilinear regression model y = b2 + b0 × [1 − exp(-x/b1)], as detailed previously (16, 17) . We conducted an intention-to-treat analysis; given that the primary outcome was the dose-relation between total vitamin D intake and achieved 25(OH)D postsupplementation, all participants who had endpoint data were included, regardless of compliance. We carried forward data from their own midpoint assessment for 7 participants who were not available at endpoint, according to best practice. Ninety-five percent prediction intervals of the required vitamin D intake were calculated to assess the probable range of intake in the target population. Moreover, the required vitamin D intakes to maintain 97.5% of the pregnant women above serum 25(OH)D thresholds of 25, 30, and 50 nmol/L were estimated from the model by inverse regression applied to the lower limits of the prediction intervals. In addition, 95% CIs for these vitamin D intakes were obtained with the use of percentiles from a nonparametric bootstrap procedure based on 1000 replications. Curvilinear regression models were fitted to all data and to data stratified by season (summer and winter). Analyses were carried out by using R version 3.2.2 (23). (27) 12 (25) 0.61 1 Values are means ± SDs unless otherwise indicated. P values are for differences between groups by ANOVA. Means in the same row without a common superscript letter differ, P < 0.05 (Tukey's test). 2 Includes intake from diet and antenatal supplements.
RESULTS
Recruitment, retention, and adverse events
Our target sample of 144 women completed the baseline visit. Serum specimens were available for all but 2 women at baseline, due to the inability to draw blood. A total of 121 women completed every visit, corresponding to an overall retention rate of 84%. The numbers of women who provided both a baseline and ≥1 follow-up sample (midpoint or endpoint) were 43, 42, and 43 for the placebo and 10-and 20-µg groups, respectively, which left a final number of 128 for the dose-response analysis. Of the 23 participants who did not provide an endpoint sample, 8 were due to a pregnancy-associated adverse event, 5 withdrew for personal reasons, 5 were lost to follow-up, 2 began consuming vitamin D supplements containing >10 µg/d and were excluded, and 3 delivered their infants before the final visit was conducted. Overall, 9 adverse events were reported: 1 sexually transmitted disorder, 1 case of gastrointestinal upset unrelated to the intervention, 1 suspected irritated uterus, 1 miscarriage, 1 chorionic hematoma, 1 symphysis pubic dysfunction, 1 case of severe hypotension, 1 case of pregnancy-induced hypertension, and 1 diagnosed case of preeclampsia. The number of adverse events and withdrawals from the trial did not differ by intervention group (P > 0.05). There were no differences in the subject characteristics between women with and without a full data set. Compliance with the intervention was high and was similar between each of the intervention arms: 79%, 87%, and 90% of participants in the placebo and 10-and 20-µg/d groups were compliant at the midpoint visit (P = 0.376) and 67%, 83%, and 76% were compliant at endpoint (P = 0.310), respectively. A detailed description of participation retention and progression throughout the study by treatment group is provided in Figure 1 .
Baseline characteristics
Participant characteristics are shown in Table 2 . Maternal age at baseline ranged from 21 to 41 y. Women in the placebo group were, on average, 3 y younger than women allocated to the highest vitamin D 3 -dose group (P = 0.004). Overall, 70% of participants had a university degree. Thirty-three percent of women were first-time mothers and 5 women were having a twin pregnancy (3 in the placebo group and 2 in the 20-μg group). Total serum 25(OH)D, iPTH, and albumin-adjusted calcium concentrations were similar between the treatment groups at baseline ( Table 3) . Baseline 25(OH)D was normally distributed, as confirmed by both Kolmogorov-Smirnov and Shapiro-Wilk tests. With a mean ± SD concentration of 54.9 ± 22.6 nmol/L, 13% had a 25(OH)D concentration <30 nmol/L and 44% had concentrations <50 nmol/L. As expected, the prevalence of women with low vitamin D status was higher in winter (November-May; 15% <30 nmol/L and 56% <50 nmol/L) than in summer (June-October; 3% <30 nmol/L and 7% <50 nmol/L). Although only 3% of mothers took a vitamin D 2 -containing supplement (dose range: 2.5-10 µg/d), 25(OH)D 2 was detectable (i.e., concentrations more than the LoD) in >98% of maternal sera, with a sample median concentration of 2.3 nmol/L, ranging from less than the LoD to 22.0 nmol/L across all time points.
Effect of vitamin D 3 supplementation on maternal serum total 25(OH)D, iPTH, and calcium
To show the impact of the intervention on maternal serum total 25(OH)D status, mean 25(OH)D concentrations at each study visit are shown in Table 3 and the prevalence of women with Serum albumin-corrected calcium values. 4 Serum iPTH was not measured at midpoint. Table 4 (1); none were in the placebo group, 5 were taking 10 µg and 6 were taking 20 µg, with average total intakes of 21.9 and 33.7 µg/d, respectively. There were no significant differences in serum calcium between treatment groups at any of the time points (Table 3) and there were no cases of hypercalcemia throughout the intervention study. There were no significant differences in serum iPTH between treatment groups at baseline or endpoint (midpoint not measured) (Table 3) , and no significant changes from baseline to endpoint (P > 0.05). There was a negative correlation between serum 25(OH)D concentrations and iPTH at both baseline (rho = −0.337, P < 0.001; n = 142) and endpoint (rho = −0.289, P = 0.006; n = 121). (Table 5) .
25(OH)D concentrations below a range of thresholds is described in
Dose-response of total vitamin D intake and maternal 25(OH)D
Umbilical cord 25(OH)D
Mean gestational age at delivery was 39 wk (range: 36-42 wk). In total, 97 umbilical cord blood samples were collected, with 96 matching maternal samples. Maternal and cord blood Calcium intakes are not presented in most studies of vitamin D in pregnancy, which adds to the variability between trial data. Disruptions in calcium homeostasis during pregnancy arise from inadequate dietary calcium or secondary hyperparathyroidism resulting from low vitamin D status. In the current study, serum iPTH was unchanged from the beginning to the end of the intervention period, irrespective of the treatment dose. Dietary recommendations for vitamin D are established with the assumption that dietary calcium intakes are adequate (1-4). In our sample, 22% had calcium intakes below the current US Estimated Average Requirement of 800 mg (1). Adolescents and ethnic minorities, who may have a higher prevalence of low calcium intakes, should be considered separately, because this may affect the vitamin D-25(OH)D dose-response relation in these groups.
Due to a lack of certainty surrounding the threshold at which the risk of hypercalcemia increases and some evidence for a reverse J-shaped relation between high 25(OH)D concentrations and adverse outcomes, caution has been urged with regard to vitamin D dosing, particularly in pregnancy (1). In the current study, no participant exceeded the Tolerable Upper Intake Level of 100 μg/d (1, 4) , which was set on the basis of avoiding the adverse effect of hypercalcemia. Although a small proportion of women (9%; n = 11) achieved a serum 25(OH)D concentration above (27, 30) . Our dosing strategy plus careful assessment of background vitamin D intakes were conservative and are a strength of the study, because this minimized risk while achieving the target 25(OH)D concentrations, albeit in a highly compliant sample.
In agreement with our recent report (9), we confirmed that 3-epi-25(OH)D 3 was present in almost all maternal and all infant cord sera, and, to our knowledge, these are the first data showing an increase in the relative expression of 3-epi-25(OH)D 3 as pregnancy progresses, independent of supplemental vitamin D intake. We have also presented the first doseresponse data of 24,25(OH) 2 This trial has a number of strengths, including CDC-accredited analysis of 25(OH)D and metabolites and the use of a method traceable to the NIST higher-order reference measurement procedure. Our vitamin D intake assessment was validated for the measurement of habitual vitamin D intake in females of different ages and has been implemented in almost 1000 trial participants to date (19) . Both compliance with the intervention and overall retention rate were high, and we detected no hypercalcemia or intervention-related adverse events. Because our sample was confined to white women, our findings are not generalizable to all women, and we recommend that the protocol be repeated in ethnicity-specific studies, because the food-frequency questionnaire would need to be tailored and the dose-response relation may vary.
In conclusion, we report evidence for an increased dietary requirement for vitamin D among white pregnant women than is currently recommended. We have shown that a total vitamin D intake of 30 µg/d is sufficient to maintain serum 25(OH)D concentrations ≥50 nmol/L in 97.5% of gravidae at high latitude and will prevent 95-99% of umbilical cord 25(OH)D concentrations falling to <25-30 nmol/L, a clinically relevant and achievable target. The question of whether pregnancy-specific thresholds based on perinatal outcomes are required is still outstanding.
